Last updated on March 2018

A Two-part Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies


Brief description of study

Two part study to evaluate the safety, tolerability, pharmacokinetics, and efficacy (in Part 2 only) of KRP203 in patients undergoing allogeneic hemopoietic stem cell transplant for hematological malignancies

Clinical Study Identifier: NCT01830010

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Paris, France

Novartis Pharmaceuticals

Novartis Investigative Site
Pessac cedex, France

Novartis Pharmaceuticals

Novartis Investigative Site
Freiburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Hamburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Jena, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Koeln, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Regensburg, Germany

Novartis Pharmaceuticals

Novartis Investigative Site
Basel, Switzerland

Novartis Pharmaceuticals

Novartis Investigative Site
Zürich, Switzerland